Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04009083 · ClinicalTrials.gov registry record · NA
Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT04009083 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 31 participants.
The verdict
NCT04009083, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a prospective outcomes study assessing quality of life and oncological control at pre-defined time points following FOCAL CRYO-ABLATION (FCA). The investigator's standard of care is to perform an Magentic Resonance Imaging (MRI) and prostate biopsy two years following FCA. The prostate biopsy assesses both the presence of in field and out of field disease. The role of Axumin PET/MRI for detecting disease following FCA has not been previously examined.
Interventions
- DEVICE Standard of Care MRI
- OTHER Fluciclovine PET scan added to MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-06-19 |
| Est. Completion | 2021-01-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04009083
The ClinicalTrials.gov registry entry for NCT04009083 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care MRI is the first listed.
NCT04009083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04009083 about?
NCT04009083 is a clinical study titled "Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)". This is a prospective outcomes study assessing quality of life and oncological control at pre-defined time points following FOCAL CRYO-ABLATION (FCA). The investigator's standard of care is to perform an Magentic Resonance Imaging (MRI) and prostate biopsy two years following FCA. The prostate biops...
What is the current status of trial NCT04009083?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2019-06-19. Estimated completion is 2021-01-07.
What interventions are being tested in trial NCT04009083?
The interventions under investigation include: Standard of Care MRI (DEVICE), Fluciclovine PET scan added to MRI (OTHER).
Who is sponsoring clinical trial NCT04009083?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.